IP Library Granted Patent US 10,745,715
Granted Patent B2
US 10,745,715 · App. 15/506,391 · Granted Aug 18, 2020

Method and means for purifying retroviral vectors

Inventors: Martin Pulé (London, GB); Leila Mekkaoui (London, GB); Gordon Weng-Kit Cheung (London, GB)
Assignee: UCL BUSINESS LTD
C12N15/86C07K14/70517C12N15/64C07K2319/03C07K2319/21C07K2319/22C07K2319/23C07K2319/50C12N2740/10041C12N2740/10051C12N2740/10052C12N2740/15043C12N2740/15051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,745,715
App. No.
15/506,391
Granted
Aug 18, 2020
Kind
B2
Abstract

The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.

Claims (34)

1. A producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors that bud from the producer cell are tagged with the tagging protein, wherein the tagging protein comprises:

i) a binding domain that comprises amino acids 2-15 of SEQ ID NO: 2 and binds to streptavidin,

ii) a membrane targeting domain that comprises a transmembrane domain and an endodomain; and

iii) a spacer connecting the binding domain to the membrane targeting domain, wherein the spacer comprises a CD8 stalk or an equivalent thereof, wherein the tagging protein has binding affinity for streptavidin that facilitates purification of the tagged retroviral vectors from cellular supernatant with a capture moiety comprising streptavidin; and wherein the binding domain binds streptavidin with a lower affinity than biotin, so that biotin may be used to elute retroviral vectors produced by the cell and captured with the capture moiety.

2. The producer cell according to claim 1 , wherein the spacer comprises a CD8 stalk or an equivalent thereof.

3. The producer cell according to claim 1 , wherein the tagging protein also comprises a cleavage site, cleavage at which releases retroviral vectors bound to a capture moiety that comprises streptavidin.

4. The producer cell according to claim 3 , wherein the tagging protein comprises a linker between the binding domain and the spacer, which linker is or comprises the cleavage site.

5. The producer cell according to claim 3 , wherein the cleavage site is a thrombin cleavage site.

6. The producer cell according to claim 1 , wherein the transmembrane domain and endodomain are the same as the transmembrane and endodomain of a retroviral vector envelope protein.

7. The producer cell according to claim 6 , which comprises the transmembrane domain and endodomain from RD-PRO envelope protein as set out in amino acids 509-565 of SEQ ID NO: 39.

8. A retroviral vector which comprises a producer cell-derived tagging protein, said tagging protein comprising:

i) a binding domain that comprises amino acids 2-15 of SEQ ID NO: 2 and binds to streptavidin,

ii) a membrane targeting domain that comprises a transmembrane domain and an endodomain; and

iii) a spacer connecting the binding domain to the membrane targeting domain, wherein the spacer comprises a CD8 stalk or an equivalent thereof, and wherein the binding domain binds streptavidin with a lower affinity than biotin, so that biotin may be used to elute the retroviral vector following capture with a capture moiety comprising streptavidin.

9. The producer cell according to claim 1 which comprises genes encoding retroviral Gag, Pol and Env proteins stably integrated within the cell genome.

10. A producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises:

i) a binding domain that comprises two or more streptavidin-binding epitopes, comprising at least one linker between the streptavidin-binding epitopes, each of said streptavidin-binding epitopes comprising amino acids 2-15 of SEQ ID NO: 2, and that binds streptavidin; and

ii) a membrane targeting domain comprising a glycosylphosphatidylinositol (GPI) anchor;

wherein the tagging protein has binding affinity for streptavidin that facilitates purification of the tagged retroviral vectors from cellular supernatant with a capture moiety comprising streptavidin; and

wherein the binding domain binds streptavidin with a lower affinity than biotin, so that biotin may be used to elute retroviral vectors produced by the cell and captured with the capture moiety.

11. The producer cell according to claim 10 , wherein the tagging protein further comprises a linker between the binding domain and the GPI anchor, which linker is or comprises a cleavage site.

12. The producer cell according to claim 10 , wherein the tagging protein further comprises a linker between the binding domain and the GPI anchor, which linker is or comprises a cleavage site.

13. A producer cell according to claim 10 , wherein the binding domain comprises the amino acid sequence shown as SEQ ID NO: 5.

14. The producer cell according to claim 10 , which comprises genes encoding retroviral Gag, Pol and Env proteins stably integrated within the cell genome.

15. A retroviral vector which comprises a producer cell-derived tagging protein, said tagging protein comprising:

i) a binding domain that comprises two or more streptavidin-binding epitopes, each of said streptavidin-binding epitopes comprising amino acids 2-15 of SEQ ID NO: 2, and further comprises at least one linker between the streptavidin-binding epitopes, wherein the binding domain binds streptavidin; and

ii) a membrane targeting domain comprising a glycosylphosphatidylinositol (GPI) anchor;

wherein the tagging protein has binding affinity for streptavidin that facilitates purification of the tagged retroviral vectors from cellular supernatant with a capture moiety comprising streptavidin; and

wherein the binding domain binds streptavidin with a lower affinity than biotin, so that biotin may be used to elute retroviral vectors captured with a capture moiety comprising streptavidin.

16. The producer cell according to claim 8 , wherein the spacer comprises a CD 8 stalk.

17. The retroviral vector according to claim 10 , wherein the tagging protein further comprises a linker between the binding domain and the GPI anchor, which linker is or comprises a cleavage site.

18. A method for making a producer cell according to claim 1 , which comprises the step of introducing a nucleic acid which encodes the tagging protein into a cell, such that the tagging protein is expressed at the cell surface.

19. A method for purifying a retroviral vector according to claim 8 which comprises a step of capturing the retroviral vector using a capture moiety that comprises streptavidin.

20. The method according to claim 19 , which also comprises a step of eluting the retroviral vector from the capture moiety with biotin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2020
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 054546/0758 →
CHANGE OF NAME Recorded Oct 9, 2019
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 050677/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: PULÉ, MARTIN; MEKKAOUI, LEILA; CHEUNG, GORDON WENG-KIT
To: UCL BUSINESS PLC
Reel/Frame 043278/0635 →
Priority Claims (1)
GB 1415344.9 · Aug 29, 2014 · national
Continuity (1)
Related Publication 20170240920A1 · Aug 24, 2017
Cited By (1)
US 12,655,388